- Home
- ENLT vs TARS Comparison
ENLT vs TARS Comparison
Compare ENLT & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- TARS
- Stock Information
- Founded
- ENLT 2008
- TARS 2016
- Country
- ENLT Israel
- TARS United States
- Employees
- ENLT N/A
- TARS N/A
- Industry
- ENLT
- TARS Medicinal Chemicals and Botanical Products
- Sector
- ENLT
- TARS Health Care
- Exchange
- ENLT Nasdaq
- TARS Nasdaq
- Market Cap
- ENLT 1.9B
- TARS 1.8B
- IPO Year
- ENLT 2023
- TARS 2020
- Fundamental
- Price
- ENLT $16.01
- TARS $46.40
- Analyst Decision
- ENLT Buy
- TARS Strong Buy
- Analyst Count
- ENLT 4
- TARS 5
- Target Price
- ENLT $19.00
- TARS $54.20
- AVG Volume (30 Days)
- ENLT 11.0K
- TARS 998.9K
- Earning Date
- ENLT 11-13-2024
- TARS 11-13-2024
- Dividend Yield
- ENLT N/A
- TARS N/A
- EPS Growth
- ENLT N/A
- TARS N/A
- EPS
- ENLT 0.41
- TARS N/A
- Revenue
- ENLT $358,416,000.00
- TARS $129,621,000.00
- Revenue This Year
- ENLT $428.35
- TARS $852.60
- Revenue Next Year
- ENLT $27.54
- TARS $74.21
- P/E Ratio
- ENLT $38.82
- TARS N/A
- Revenue Growth
- ENLT 47.65
- TARS 801.96
- 52 Week Low
- ENLT $14.09
- TARS $15.60
- 52 Week High
- ENLT $20.00
- TARS $52.99
- Technical
- Relative Strength Index (RSI)
- ENLT 50.90
- TARS 61.40
- Support Level
- ENLT $14.96
- TARS $44.00
- Resistance Level
- ENLT $16.48
- TARS $52.99
- Average True Range (ATR)
- ENLT 0.50
- TARS 3.12
- MACD
- ENLT 0.06
- TARS -0.50
- Stochastic Oscillator
- ENLT 71.13
- TARS 32.34
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. It operates across the three largest renewable segments namely solar, wind and energy storage. Geographically, it operates in the United States, Israel and 9 European countries.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.